{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:35:01Z","timestamp":1792251301587,"version":"4.4.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jhep.2019.12.028","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T11:52:35Z","timestamp":1579693955000},"page":"1097-1104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1"],"prefix":"10.1016","volume":"72","author":[{"given":"Michelle","family":"Spaan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dazhuang","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Horner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff","family":"Dusheiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2019.12.028_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(10)61931-9","article-title":"Hepatitis delta virus","volume":"378","author":"Hughes","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2019.12.028_bib2","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nrgastro.2016.126","article-title":"Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options","volume":"13","author":"Lempp","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.12.028_bib3","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/gut.46.3.420","article-title":"Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep)","volume":"46","author":"Fattovich","year":"2000","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2019.12.028_bib4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/liv.13018","article-title":"The adventure of delta","volume":"36","author":"Rizzetto","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2019.12.028_bib5","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1128\/JCM.02297-13","article-title":"Characterization of hepatitis delta virus in sub-Saharan Africa","volume":"52","author":"Andernach","year":"2014","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.jhep.2019.12.028_bib6","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/hep.21590","article-title":"Hepatitis D virus infection\u2013not a vanishing disease in Europe!","volume":"45","author":"Wedemeyer","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.12.028_bib7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/jmv.21078","article-title":"The increasing prevalence of hepatitis delta virus (HDV) infection in South London","volume":"80","author":"Cross","year":"2008","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.jhep.2019.12.028_bib8","first-page":"521","article-title":"A\u00a0re-assessment of the epidemiology and patient characteristics of hepatitis D virus infection in inner city London","volume":"66","author":"William Tong","year":"2013","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.jhep.2019.12.028_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrgastro.2009.205","article-title":"Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead","volume":"7","author":"Wedemeyer","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.12.028_bib10","doi-asserted-by":"crossref","first-page":"e101002","DOI":"10.1371\/journal.pone.0101002","article-title":"Anti-HDV IgM as a marker of disease activity in hepatitis delta","volume":"9","author":"Wranke","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2019.12.028_bib11","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1128\/JVI.78.5.2537-2544.2004","article-title":"Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades","volume":"78","author":"Radjef","year":"2004","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2019.12.028_bib12","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3201\/eid1209.060112","article-title":"Eighth major clade for hepatitis delta virus","volume":"12","author":"Le Gal","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jhep.2019.12.028_bib13","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1128\/JCM.02142-07","article-title":"Prevalence and genetic diversity of hepatitis B and delta viruses in pregnant women in Gabon: molecular evidence that hepatitis delta virus clade 8 originates from and is endemic in central Africa","volume":"46","author":"Makuwa","year":"2008","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.jhep.2019.12.028_bib14","doi-asserted-by":"crossref","first-page":"9016","DOI":"10.1073\/pnas.90.19.9016","article-title":"A\u00a0genotype of hepatitis D virus that occurs in northern South America","volume":"90","author":"Casey","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2019.12.028_bib15","doi-asserted-by":"crossref","first-page":"7226","DOI":"10.1128\/jvi.69.11.7226-7231.1995","article-title":"Hepatitis delta virus mutant: effect on RNA editing","volume":"69","author":"Wu","year":"1995","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhep.2019.12.028_bib16","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1053\/j.gastro.2006.01.035","article-title":"Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients","volume":"130","author":"Su","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.12.028_bib17","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1099\/vir.0.19499-0","article-title":"Chronic hepatitis delta virus infection with genotype IIb variant is correlated with progressive liver disease","volume":"84","author":"Watanabe","year":"2003","journal-title":"J\u00a0Gen Virol"},{"key":"10.1016\/j.jhep.2019.12.028_bib18","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/hep.21325","article-title":"Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up","volume":"44","author":"Castelnau","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.12.028_bib19","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1478-3231.2006.01279.x","article-title":"Treatment of chronic hepatitis delta with pegylated interferon-alpha2b","volume":"26","author":"Erhardt","year":"2006","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2019.12.028_bib20","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2019.12.028_bib21","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/infdis\/jix656","article-title":"Interferon treatment duration in patients with chronic delta hepatitis and its effect on the natural course of the disease","volume":"217","author":"Yurdaydin","year":"2018","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhep.2019.12.028_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jviromet.2012.05.008","article-title":"Development and validation of an efficient in-house real-time reverse transcription polymerase chain reaction assay for the quantitative detection of serum hepatitis delta virus RNA in a diverse South London population","volume":"184","author":"Shang","year":"2012","journal-title":"J\u00a0Virol Methods"},{"key":"10.1016\/j.jhep.2019.12.028_bib23","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1365-2893.2009.01144.x","article-title":"Virological and clinical characteristics of delta hepatitis in Central Europe","volume":"16","author":"Heidrich","year":"2009","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2019.12.028_bib24","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1053\/j.gastro.2009.01.052","article-title":"A\u00a028-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma","volume":"136","author":"Romeo","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.12.028_bib25","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1365-2893.2010.01324.x","article-title":"Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study","volume":"18","author":"Buti","year":"2011","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2019.12.028_bib26","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1128\/JCM.01822-10","article-title":"High prevalence and predominance of hepatitis delta virus genotype 1 infection in Cameroon","volume":"49","author":"Foupouapouognigni","year":"2011","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.jhep.2019.12.028_bib27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcv.2012.05.011","article-title":"Virological and epidemiological features of hepatitis delta infection among blood donors in Nouakchott, Mauritania","volume":"55","author":"Mansour","year":"2012","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.jhep.2019.12.028_bib28","doi-asserted-by":"crossref","first-page":"e99971","DOI":"10.1371\/journal.pone.0099971","article-title":"Hepatitis B and Delta virus are prevalent but often subclinical coinfections among HIV infected patients in Guinea-Bissau, West Africa: a cross-sectional study","volume":"9","author":"Honge","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2019.12.028_bib29","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jhep.2010.06.008","article-title":"Outcome of chronic delta hepatitis in Italy: a long-term cohort study","volume":"53","author":"Niro","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2019.12.028_bib30","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/hep.28876","article-title":"Antiviral treatment and liver-related complications in hepatitis delta","volume":"65","author":"Wranke","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.12.028_bib31","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0006-291X(03)01076-3","article-title":"Initiation of RNA replication of cloned Taiwan-3 isolate of hepatitis delta virus genotype II in cultured cells","volume":"306","author":"Lin","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhep.2019.12.028_bib32","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1002\/hep.26718","article-title":"Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study","volume":"59","author":"Hsu","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.12.028_bib33","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.21296","article-title":"Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta","volume":"44","author":"Niro","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.12.028_bib34","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27102","article-title":"Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta","volume":"60","author":"Heidrich","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.12.028_bib35","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/135965350501000603","article-title":"Two-year interferon therapy with or without ribavirin in chronic delta hepatitis","volume":"10","author":"Gunsar","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2019.12.028_bib36","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1365-2893.2007.00936.x","article-title":"Treatment of chronic delta hepatitis with lamivudine vs lamivudine\u00a0+ interferon vs interferon","volume":"15","author":"Yurdaydin","year":"2008","journal-title":"J\u00a0Viral Hepat"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820300234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820300234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:37:07Z","timestamp":1759174627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827820300234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0168827820300234"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2019.12.028","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2019.12.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}